RNAi Archives -

successfully develop targeted extrahepatic RNAi drugs

The 3rd Annual RNAi – Based Therapeutics Summit Returns!

https://pharmaphorum.com/events/the-3rd-annual-rnai-based-therapeutics-summit-returns/

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

Phil Taylor Dicerna, gene silencing, M&A, Novo Nordisk, RNAi 0 Comment

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

https://pharmaphorum.com/news/novo-nordisk-snaps-up-rnai-partner-dicerna-in-3-3bn-takeover-deal/

Market Access/ News/ News

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

Phil Taylor cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi 0 Comment

Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help

NICE backs NHS use of Novartis’ cholesterol drug Leqvio

https://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/

News/ News/ R&D

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Phil Taylor Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi 0 Comment

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

https://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/

Podcast/ R&D/ Views & Analysis/ Views and analysis

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

Dominic Tyer Alnylam, coronavirus, COVID-19, gene silencing, podcast, RNAi 0 Comment

Alnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing

Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast

https://pharmaphorum.com/r-d/alnylam-gene-silencing-biotech-podcast/

News/ News/ R&D

Sanofi and Alnylam conclude research phase of RNAi alliance

George Underwood Alnylam, Genzyme, RNAi, Sanofi 0 Comment

Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance

Sanofi and Alnylam conclude research phase of RNAi alliance

https://pharmaphorum.com/news/sanofi-and-alnylam-conclude-research-phase-of-rnai-alliance/

News/ R&D/ Rare diseases

Alnylam hopes for 2018 filing for RNAi liver disease drug

Richard Staines Alnylam, Biotech, hepatology, Ionis, RNAi 0 Comment

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018

Alnylam hopes for 2018 filing for RNAi liver disease drug

https://pharmaphorum.com/news/alnylam-hopes-2018-filing-rnai-liver-disease-drug/

News

Sanofi passes on Alnylam’s breakthrough therapy

Linda Banks Alnylam, breakthrough Therapy, patisiran, rare disease, RNAi, Sanofi 0 Comment

Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt

Sanofi passes on Alnylam’s breakthrough therapy

https://pharmaphorum.com/news/sanofi-passes-alnylams-breakthrough-therapy/

Oncology/ Partner content/ Partner Content/ Press releases/ R&D

Topics Presented this February 2018 at RNA Therapeutics

Pavan Solanki cancer, dna, rna, RNAi, therapeutics 0 Comment

RNA Therapeutics 2018

Topics Presented this February 2018 at RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/topics-presented-this-february-2018-at-rna-therapeutics/

Trending

RNAi

Login